Weber E - Search Results

1

Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.

Jogiraju V, Weber E, Hindman J, West S, Ling J, Rhee M, Girish S, Palaparthy R, Singh R. Jogiraju V, et al. Among authors: weber e. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0134423. doi: 10.1128/aac.01344-23. Epub 2024 Mar 8. Antimicrob Agents Chemother. 2024. PMID: 38456707 Free PMC article.

2

Pharmacokinetics, Disposition, and Biotransformation of [¹⁴C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion.

Weber E, Subramanian R, Rowe W, Graupe M, Ling J, Shen G, Begley R, Sager J, Wolckenhauer S, Rhee M, Palaparthy R, Singh R. Weber E, et al. Clin Pharmacokinet. 2024 Feb;63(2):241-253. doi: 10.1007/s40262-023-01328-1. Epub 2024 Jan 18. Clin Pharmacokinet. 2024. PMID: 38236562

3

Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment.

Younis IR, Nelson C, Weber EJ, Qin AR, Watkins TR, Othman AA. Younis IR, et al. J Clin Pharmacol. 2024 Jul;64(7):878-886. doi: 10.1002/jcph.2427. Epub 2024 Mar 22. J Clin Pharmacol. 2024. PMID: 38520128 Clinical Trial.

4

Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants.

Younis IR, Nelson C, Weber EJ, Shen G, Qin AR, Xiao D, Watkins TR, Othman AA. Younis IR, et al. J Clin Pharmacol. 2024 Dec;64(12):1586-1593. doi: 10.1002/jcph.6114. Epub 2024 Aug 30. J Clin Pharmacol. 2024. PMID: 39213138 Clinical Trial.

5

Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.

Weber E, Younis IR, Nelson C, Ding D, Qin A, Xiao D, Watkins TR, Othman AA. Weber E, et al. J Clin Pharmacol. 2023 May;63(5):560-568. doi: 10.1002/jcph.2206. Epub 2023 Feb 28. J Clin Pharmacol. 2023. PMID: 36700458 Clinical Trial.

6

Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.

Weber EJ, Younis IR, Wang L, Xiao D, Barchuk WT, Othman AA. Weber EJ, et al. Clin Pharmacol Drug Dev. 2024 Jun;13(6):677-687. doi: 10.1002/cpdd.1384. Epub 2024 Feb 12. Clin Pharmacol Drug Dev. 2024. PMID: 38346861 Clinical Trial.

7

Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.

Younis I, Weber E, Nelson C, Kirby BJ, Shen G, Xiao D, Watkins TR, Othman AA. Younis I, et al. Among authors: weber e. Clin Pharmacokinet. 2023 Apr;62(4):609-621. doi: 10.1007/s40262-023-01214-w. Epub 2023 Mar 11. Clin Pharmacokinet. 2023. PMID: 36906733 Free PMC article.

8

Assessing the Impact and Cost-Effectiveness of Exposome Interventions on Alzheimer's Disease: A Review of Agent-Based Modeling and Other Data Science Methods for Causal Inference.

Liu SH, Weber ES, Manz KE, McCarthy KJ, Chen Y, Schüffler PJ, Zhu CW, Tracy M. Liu SH, et al. Among authors: weber es. Genes (Basel). 2024 Nov 12;15(11):1457. doi: 10.3390/genes15111457. Genes (Basel). 2024. PMID: 39596657 Free PMC article. Review.

9

TET2 regulates early and late transitions in exhausted CD8⁺ T cell differentiation and limits CAR T cell function.

Dimitri AJ, Baxter AE, Chen GM, Hopkins CR, Rouin GT, Huang H, Kong W, Holliday CH, Wiebking V, Bartoszek R, Drury S, Dalton K, Koucky OM, Chen Z, Giles JR, Dils AT, Jung IY, O'Connor R, Collins S, Everett JK, Amses K, Sherrill-Mix S, Chandra A, Goldman N, Vahedi G, Jadlowsky JK, Young RM, Melenhorst JJ, Maude SL, Levine BL, Frey NV, Berger SL, Grupp SA, Porter DL, Herbst F, Porteus MH, Carty SA, Bushman FD, Weber EW, Wherry EJ, Jordan MS, Fraietta JA. Dimitri AJ, et al. Among authors: weber ew. Sci Adv. 2024 Nov 15;10(46):eadp9371. doi: 10.1126/sciadv.adp9371. Epub 2024 Nov 13. Sci Adv. 2024. PMID: 39536093 Free PMC article.

10

Synthesis and Docking Studies of Novel Spiro[5,8-methanoquinazoline-2,3'-indoline]-2',4-dione Derivatives.

Faragó T, Mészáros R, Wéber E, Palkó M. Faragó T, et al. Among authors: weber e. Molecules. 2024 Oct 29;29(21):5112. doi: 10.3390/molecules29215112. Molecules. 2024. PMID: 39519753 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,992 results

Search Page

Filters